0001104659-21-078158.txt : 20210608
0001104659-21-078158.hdr.sgml : 20210608
20210608142624
ACCESSION NUMBER: 0001104659-21-078158
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210604
FILED AS OF DATE: 20210608
DATE AS OF CHANGE: 20210608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sabba Stephen L
CENTRAL INDEX KEY: 0001442372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 211001894
MAIL ADDRESS:
STREET 1: DORSET MANAGEMENT CORP
STREET 2: 485 UNDERHILL BLVD SUITE 205
CITY: SYOSSET
STATE: NY
ZIP: 11791
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
tm2119120-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-04
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001442372
Sabba Stephen L
DORSET MANAGEMENT CORP
485 UNDERHILL BLVD SUITE 205
SYOSSET
NY
11791
1
0
0
0
Common Stock
2021-06-04
4
A
0
630
0.00
A
25061
D
Non-Qualified Stock Option (right to buy)
115.39
2021-06-04
4
A
0
3269
0
D
2031-06-04
Common Stock
3269
3269
D
Non-Qualified Stock Option (right to buy)
117.58
2030-06-10
Common Stock
2468
2468
D
These securities, as represented in Column 5, include a grant of 630 restricted shares approved by the Board of Directors of the Company at the 2021 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
These securities, as represented in Column 5, were acquired by a grant of 3,269 shares approved by the Board of Directors of the Company at the 2021 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time.
These securities, as represented in Column 5, were acquired by a grant of 2,468 shares approved by the Board of Directors of the Company at the 2020 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 12, 2020.
/s/Stephen L. Sabba
2021-06-08